Brief: FDA Approves IND Submission Allowing ABVC Biopharma To Proceed With Clinical Study Of Abv-1519 To Treat Non-Small Cell Lung Cancer
05/01/2023 15:08
Jan 5 (Reuters) - ABVC Biopharma Inc ABVC.O :
* FDA APPROVES IND SUBMISSION ALLOWING ABVC BIOPHARMA TO
PROCEED
WITH CLINICAL STUDY OF ABV-1519 FOR TREATMENT OF NON-SMALL CELL
LUNG CANCER
Source text for Eikon: ID:nGNX5Js99x
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner